Mestag Therapeutics

Who: Mestag/Merck & Co What: The UK biotech has entered into a license and collaboration agreement with the US behemoth to identify targets for the development of therapies against inflammatory dis

Dealmaking between big pharma and biotech is an integral part of the industry ecosystem, and yet it remains as much an art as a science – and as much about personal chemistry as about drug chemistry (

After a six-month search to find a permanent replacement for research chief John Reed, Sanofi has dipped into the venture capital sector and appointed Houman Ashrafian as its new head of R&D, effect

Venture capital mega-rounds of $100m or more are driving record levels of VC investment in biopharmaceutical companies, and these big financings have not taken a summer break. [Sidebar#SC144714] The l